Overview
The goal of this clinical trial is to evaluate whether daily supplementation with cold-pressed pecan nut oil can reduce inflammation in adults with overweight. The main questions it aims to answer are:
Does pecan nut oil supplementation reduce inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)? Does pecan nut oil supplementation improve biochemical parameters such as fasting blood glucose and lipid profile? Researchers will compare an experimental group receiving pecan nut oil to a control group with no intervention to determine its effect on inflammation and metabolic parameters.
Participants will:
Consume 30 g/day of cold-pressed pecan nut oil under fasting conditions for 8 weeks (experimental group) Maintain their usual diet and physical activity throughout the study Attend two evaluation visits (baseline and Day 60) for blood sample collection and anthropometric measurements Provide dietary information using a 24-hour dietary recall
Eligibility
Inclusion Criteria:
- Adults aged 18 to 65 years
- Body mass index (BMI) ≥25 and \<30 kg/m² (overweight)
- Willingness to participate and provide written informed consent
- Ability to comply with study procedures and attend scheduled visits
- Stable dietary habits and physical activity levels during the study period
Exclusion Criteria:
- Diagnosis of chronic diseases such as diabetes mellitus, cardiovascular disease, liver disease, renal disease, or autoimmune disorders
- Use of anti-inflammatory medications, lipid-lowering drugs, or dietary supplements within the last 3 months
- Smoking or excessive alcohol consumption
- Pregnancy or lactation
- Known allergy or intolerance to nuts or nut-derived products
- Participation in another clinical trial within the last 3 months
- Any condition that, in the investigator's opinion, may interfere with study participation or outcomes
